Table I.
Association between the expression of CITED1 and clinicopathological features in The Cancer Genome Atlas cohort.
| Clinicopathological features | Low CITED1 expression (n=187), n (%) | High CITED1 expression (n=188), n (%) | P-value |
|---|---|---|---|
| Age (years) | 0.214 | ||
| Mean ± SD | 45.5±15.4 | 47.5±15.3 | |
| ≤45 | 94 (50.3) | 82 (43.6) | |
| >45 | 93 (49.7) | 106 (56.4) | |
| Gender | 0.228 | ||
| Male | 54 (28.9) | 44 (23.4) | |
| Female | 133 (71.1) | 144 (76.6) | |
| Tumor size (cm) | 0.835 | ||
| Mean | 3.03±1.77 | 2.79±1.64 | |
| ≤1 | 15 (8.0) | 14 (7.4) | |
| >1 | 172 (92.0) | 174 (92.6) | |
| Lymph node metastasis | 0.006 | ||
| No | 95 (50.8) | 69 (36.7) | |
| Yes | 92 (49.2) | 119 (63.3) | |
| Clinical stage | 0.003 | ||
| I+II | 131 (70.1) | 104 (55.3) | |
| III+IV | 56 (29.9) | 84 (44.7) | |
| Histological type | 0.935 | ||
| Classical | 134 (71.7) | 134 (71.3) | |
| Other | 53 (28.3) | 54 (28.7) |
CITED1, Cbp/p300-interacting transactivators with glutamic acid [E] and aspartic acid [D]-rich C-terminal domain 1; SD, standard deviation.